Higher baseline calprotectin was independently associated with an increased risk of fatal or non-fatal CVD events (29 and 44 total events at 5 and 10 years) in patients with moderate CKD.
Cohort (n=153)
Does higher baseline calprotectin predict fatal or non-fatal CVD events in patients with moderate CKD?
Calprotectin may serve as an independent prognostic biomarker for future cardiovascular events in patients with moderate chronic kidney disease, potentially outperforming CRP.
Chronic kidney disease (CKD) and low-grade inflammation are associated with increased risk of cardiovascular disease (CVD). Calprotectin, a protein mainly secreted by activated neutrophils during inflammatory conditions, has been linked to CVD risk in general populations. The aim of this study was to evaluate the association of calprotectin with CVD risk in CKD patients, relative to C-reactive protein (CRP). One hundred and fifty-three patients with moderate CKD were prospectively followed up at 5 and 10 years. We used Cox regression modelling with stepwise adjustments for other relevant covariates (age, sex, cystatin C, previous CVD, systolic blood pressure, HDL cholesterol and HbA1c) to assess the association of baseline calprotectin and CRP with the risk of fatal or non-fatal CVD events. Twenty-nine and 44 patients experienced a CVD event during median follow-up of 4.8 and 10.9 years, respectively. Higher calprotectin was associated with increased CVD risk at both time points, which remained statistically significant after multivariable adjustments, including adjustment for CRP. For CRP, the associations did not remain statistically significant after final multivariable adjustments. In conclusion, we have shown that in patients with CKD, calprotectin was independently associated with the risk of future CVD events, suggesting that calprotectin may provide prognostic information of CVD risk.
Løfblad et al. (Fri,) conducted a cohort in Chronic kidney disease (n=153). Baseline calprotectin was evaluated on Fatal or non-fatal CVD events. Higher baseline calprotectin was independently associated with an increased risk of fatal or non-fatal CVD events (29 and 44 total events at 5 and 10 years) in patients with moderate CKD.